- Article metrics
- Last updated: Fri, 19 Apr 2024 10:14:40 Z
Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
Access & Citations
-
- 2343
- Article Accesses
-
- 0
- Web of Science
-
- 1
- CrossRef
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.